CervoMed Inc.

CervoMed Inc. held its 2026 Annual Meeting of Stockholders on June 8, 2026, with a quorum of 67.2% of outstanding shares. Stockholders elected eight directors, ratified RSM US LLP as the independent auditor for 2026, and approved, on an advisory basis, the compensation of named executive officers for 2024. Additionally, Amendment No. 1 to the 2025 Equity Incentive Plan was approved.

CervoMed Inc. reported a net loss of $8.0 million for Q1 2026, an increase from $4.9 million in Q1 2025, primarily due to decreased grant revenue and higher operating expenses. The company's cash, cash equivalents, and marketable securities stood at $12.9 million as of March 31, 2026, providing a cash runway into September 2026. Despite financial challenges, CervoMed made significant clinical progress, including finalizing the Phase 3 trial design for neflamapimod in Dementia with Lewy Bodies (DLB) and presenting positive MRI and biomarker data, though the trial is subject to financing.

CervoMed reported a Q1 2026 net loss of $8.0 million, an increase from $4.9 million in Q1 2025, with cash and equivalents decreasing to $12.9 million, providing a runway into Q3 2026. The company made significant progress in its clinical programs, finalizing the design for its planned Phase 3 trial of neflamapimod in Dementia with Lewy Bodies (DLB), subject to financing, and expects to initiate it in H2 2026. Positive MRI data and biomarker analyses for neflamapimod in DLB were presented at AAN and AD/PD 2026, respectively, reinforcing its potential as a disease-modifying treatment. Enrollment for the Phase 2a trial in nfvPPA is complete in the US, and neflamapimod was selected for the EXPERTS-ALS platform.

CervoMed Inc. reported a significantly wider net loss of $7.96 million for Q1 2026, compared to a $4.89 million net loss in Q1 2025. The company also disclosed substantial doubt about its ability to continue as a going concern, as its $12.9 million in cash, cash equivalents, and marketable securities are insufficient to fund operations for the next twelve months. Grant revenue ceased in Q1 2026, contributing to increased operating losses and cash burn.

CervoMed Inc. announced positive data from its Phase 2b RewinD-LB trial at the 2026 American Academy of Neurology Annual Meeting. The data indicated that neflamapimod, the company's drug candidate, successfully increased basal forebrain volume and functional connectivity in patients suffering from dementia with Lewy bodies. This presentation highlights a significant step in the development of neflamapimod for this neurological condition.

CervoMed Inc. presented MRI analyses at the 2026 AAN Annual Meeting, demonstrating that neflamapimod may increase the size and enhance the function of the basal forebrain in patients with dementia with Lewy bodies (DLB). These findings from further analysis of the RewinD-LB Phase 2b clinical trial are consistent with preclinical data, suggesting that basal forebrain atrophy in DLB might be reversible. The company believes neflamapimod acts on the underlying cause of DLB and plans to incorporate this MRI technology into a planned Phase 3 trial in DLB patients, subject to financing, later this year.

CervoMed Inc. (CRVO) announced on April 7, 2026, that company representatives will present key aspects of its neflamapimod clinical program. The presentation is scheduled to take place on the same day, April 7, 2026, at the 2026 Lewy Body Dementia Association Annual Meeting in Atlanta, GA. This event provides a platform for CervoMed to disseminate information regarding its lead clinical candidate to the scientific and medical community, potentially enhancing awareness and understanding of its therapeutic pipeline. For institutional investors, this signifies ongoing development and communication regarding the company's core assets in the neurodegenerative disease space.